US biopharmaceutical company Pfizer Inc (NYSE:PFE) announced on Wednesday that it has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop and commercialise three preclinical in vivo chimeric antigen receptor T-cell (CAR-T) programmes targeting autoimmune diseases outside Greater China.
The agreement also grants Pfizer rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, as well as oncology.
Starna will receive an upfront payment of USD330m and is eligible for up to USD2.3bn in development and commercial milestone payments, in addition to royalties on net sales of approved products. Pfizer will lead clinical development outside Greater China and manufacture finished drug products for initial clinical trials at its US facilities.
Pfizer will retain exclusive commercialisation rights outside Greater China and hold options to expand its licensing territory to include the region. The agreement also provides options to exclusively license compounds developed under a separate research collaboration.
The deal expands Pfizer's Inflammation and Immunology pipeline, leveraging its expertise in RNA delivery, immunology research, clinical development and commercialisation to advance next-generation cell therapies for autoimmune diseases and cancer.
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
argenx reports positive Phase 2 results for FB102 in coeliac disease
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
Abogen enters Novartis licensing and option agreement to advance RNA programs
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA